Comparative Pharmacology
Head-to-head clinical analysis: ISOPROTERENOL HYDROCHLORIDE versus ISUPREL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOPROTERENOL HYDROCHLORIDE versus ISUPREL.
ISOPROTERENOL HYDROCHLORIDE vs ISUPREL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-adrenergic agonist with non-selective affinity for β1 and β2 receptors; increases myocardial contractility, heart rate, and bronchodilation via Gs-protein activation and cAMP elevation.
Nonselective beta-adrenergic agonist with predominant beta-1 and beta-2 receptor stimulation, leading to increased heart rate, contractility, and bronchodilation.
Initial IV infusion: 0.5-5 mcg/min, titrated to heart rate and blood pressure; typical range 2-10 mcg/min. IV bolus: 10-20 mcg as needed. Continuous infusion: 0.01-0.5 mcg/kg/min (max 30 mcg/min).
Adult: 0.5-5 mcg/min IV infusion titrated to effect; bolus: 10-20 mcg IV push. Sublingual: 10-20 mg 3-4 times daily.
None Documented
None Documented
Terminal elimination half-life is 2-3 minutes; clinically, catechol-O-methyltransferase (COMT)-mediated metabolism leads to rapid clearance.
Terminal elimination half-life is approximately 2.5-3 hours in adults. In neonates and infants, half-life may be longer (up to 6-8 hours). Clinical context: Short half-life necessitates continuous infusion for sustained effect in acute settings.
Primarily renal excretion of sulfate conjugates and unchanged drug; biliary/fecal excretion is minimal.
Primarily renal excretion of unchanged drug and conjugates; approximately 50-70% excreted in urine within 24 hours (mostly as sulfate conjugates, with about 10-15% unchanged), and less than 5% in feces.
Category C
Category C
Beta-Adrenergic Agonist
Beta-Adrenergic Agonist